JPMorgan Chase & Co. is extending its US$1.5-trillion Security and Resiliency Initiative (SRI) to Canada, aiming to support key sectors like energy, defence, and critical minerals through financing and investments. While no specific allocation is set for Canada, the bank expects to deploy billions into the country. This expansion aligns with Ottawa's efforts to attract investment and build national infrastructure, focusing on areas like supply chains, advanced manufacturing, and strategic technologies.

MYDA Advisors LLC significantly increased its stake in AT&T Inc. ($T) by 136.7% in the fourth quarter, now holding 355,069 shares valued at $8.82 million. This move is part of a broader trend where several institutional investors boosted their positions, leading to 57.10% of AT&T shares being institutionally held. The company also reported strong quarterly earnings, beating expectations, and offers a substantial 4.7% dividend yield.

This extensive stock analysis of PharmaCyte Biotech (Nasdaq: PMCB) provides an overview of the company's financials, performance, and recent news. The biotechnology company, focused on developing cellular therapies for cancer, currently has a small market cap of US$8.2m and no revenue, facing challenges such as shareholder dilution, volatile share prices, and non-compliance notices from Nasdaq regarding its minimum bid price requirement. The article also highlights the company's efforts to address an FDA clinical hold on its pancreatic cancer treatment and outlines ongoing studies and management changes.

Atlas Capital Advisors Inc. has made a new $1.15 million investment in Williams-Sonoma, Inc., purchasing 6,430 shares during the fourth quarter. Williams-Sonoma reported better-than-expected quarterly earnings and revenue, along with announcing a quarterly dividend of $0.76 per share. The stock currently holds a "Moderate Buy" consensus rating from analysts with an average target price of $211.47.

Atlas Capital Advisors Inc. has made a new investment in Johnson & Johnson, purchasing 5,769 shares valued at approximately $1.19 million in the fourth quarter. This comes as Johnson & Johnson reported strong Q1 results, beating EPS and revenue estimates, and raised its quarterly dividend. The stock maintains a "Moderate Buy" consensus among analysts with an average price target of $253.04.

Aptus Capital Advisors LLC increased its stake in American Express Company (NYSE:AXP) by 19.6% in the fourth quarter, bringing its total holdings to 47,299 shares valued at $17,498,000. Other institutional investors also adjusted their positions in AXP, which maintains a "Hold" consensus rating from analysts with an average target price of $359.05. American Express reported strong quarterly earnings, exceeding analyst expectations, and announced a quarterly dividend of $0.95 per share.

Barclays PLC reduced its stake in Monster Beverage Corporation (MNST) by 4.8% during the fourth quarter, selling 239,389 shares, though still holding approximate 4.75 million shares worth around $364 million. Insider selling also occurred, with CFO Thomas J. Kelly and insider Emelie Tirre selling a total of 178,700 shares valued at about $15.5 million. Despite this, Monster Beverage reported strong quarterly earnings, beating estimates with $0.58 EPS and $2.32 billion in revenue, and authorized a $500 million share repurchase program.

Atlas Capital Advisors Inc. has made a new investment in Altria Group, acquiring 13,953 shares valued at approximately $805,000 during the fourth quarter. While institutional ownership of Altria is high at 57.41%, two directors recently sold portions of their holdings. Analysts currently rate Altria Group as a "Hold" with an average price target of $70.44, and the company recently declared a quarterly dividend of $1.06, offering a yield of 5.9%.

Barclays PLC significantly increased its stake in O'Reilly Automotive, adding over 332,000 shares in the fourth quarter, bringing its total holding to 3.11 million shares valued at approximately $283.5 million. This increase follows O'Reilly's strong quarterly earnings, which surpassed analyst expectations with an EPS of $0.72 and revenue of $4.56 billion. Analysts maintain a "Moderate Buy" rating for ORLY, with an average target price of $112.25, although some insider selling has also been reported.

Arax Advisory Partners significantly reduced its stake in PepsiCo (NASDAQ:PEP) during the fourth quarter, selling 199,263 shares and decreasing its position by 88.6% to 25,531 shares valued at $3.66 million. Despite this sale, institutional ownership in PepsiCo remains high, with major firms like Vanguard and State Street increasing their holdings. The company recently reported strong quarterly results, beating EPS and revenue estimates, and raised its quarterly dividend to $1.48 per share, resulting in a 4.1% annualized yield.